Cutler Group LP Biocryst Pharmaceuticals Inc Put Options Transaction History

Cutler Group LP

12 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2022 Oct 25, 2022	BUY	$10.79 - $14.81 $7,552 - $10,367	700 New	700 $0
Q1 2022 Apr 14, 2022	SELL	$11.56 - $19.76 $27,744 - $47,424	-2,400 Reduced 82.76%	500 $0
Q4 2021 Jan 18, 2022	SELL	$11.18 - $15.46 $251,550 - $347,850	-22,500 Reduced 88.58%	2,900 $2,000
Q3 2021 Oct 26, 2021	BUY	$14.21 - $17.65 $206,045 - $255,924	14,500 Added 133.03%	25,400 $47,000
Q2 2021 Jul 19, 2021	BUY	$9.5 - $17.24 $103,550 - $187,915	10,900 New	10,900 $24,000
Q3 2020 Oct 27, 2020	SELL	$3.43 - $5.53 $7,203 - $11,613	-2,100 Closed	0 $0
Q2 2020 Jul 22, 2020	BUY	$1.9 - $5.61 $3,990 - $11,781	2,100 New	2,100 $0
Q3 2019 Oct 28, 2019	SELL	$2.5 - $3.73 $1,500 - $2,238	-600 Closed	0 $0
Q2 2019 Aug 09, 2019	SELL	$2.91 - $9.15 $30,264 - $95,160	-10,400 Reduced 94.55%	600 $0
Q4 2018 Feb 05, 2019	BUY	$6.51 - $9.6 $20,181 - $29,760	3,100 Added 39.24%	11,000 $6,000
Q3 2018 Nov 07, 2018	BUY	$5.52 - $7.99 $4,968 - $7,191	900 Added 12.86%	7,900 $5,000
Q3 2017 Oct 17, 2017	BUY	$4.1 - $5.97 $28,699 - $41,790	7,000	7,000 $2,000

279

172M

625K

739K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.41B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.